Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jingxin Pharma In-licenses China Rights to Insomnia Drug

publication date: Oct 28, 2010
Zhejiang Jingxin Pharmaceutical has in-licensed the China rights to an insomnia drug candidate from Evotec AG of Germany. Jingxin Pharma will have exclusive China rights to the EVT 201, a novel, clinical-stage insomnia treatment. Evotec will receive a small upfront payment, plus commercial milestones and royalties that Evotec called “significant.” More details....

Stock Symbol: (Frankfurt: EVT)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital